Date published: 2026-5-16

1-800-457-3801

SCBT Portrait Logo
Seach Input

CRM1 Inhibitors

CRM1 inhibitors belong to a class of compounds designed to target Chromosome Region Maintenance 1 (CRM1), also known as Exportin 1, a critical mediator of nuclear export. CRM1 plays a fundamental role in nucleocytoplasmic transport by facilitating the export of numerous proteins and RNA molecules from the nucleus to the cytoplasm. This export process is vital for regulating cellular functions, including gene expression, cell cycle progression, signal transduction, and apoptosis. CRM1 recognizes and binds to nuclear export signals (NES) present on cargo proteins, forming a ternary complex with the cargo and the nuclear pore complex, thereby enabling their translocation across the nuclear envelope.

Inhibitors targeting CRM1 aim to interfere with its function in the export of proteins and RNA molecules by binding to specific regions of the CRM1 protein or by blocking the binding site for cargo molecules. By inhibiting CRM1, these compounds disrupt the normal nuclear export of critical proteins and RNA, leading to aberrant cellular processes and dysregulation of pathways reliant on the precise spatial and temporal localization of these molecules.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

KPT 330

1393477-72-9sc-489062
5 mg
$173.00
(0)

Selinexor is researched for certain types of relapsed or refractory cancers, including multiple myeloma and diffuse large B-cell lymphoma.

Verdinexor

1392136-43-4sc-492602
5 mg
$395.00
(0)

Another XPO1 inhibitor developed by Karyopharm Therapeutics, which has been studied for various cancers.

Leptomycin B

87081-35-4sc-358688
sc-358688A
sc-358688B
50 µg
500 µg
2.5 mg
$107.00
$416.00
$1248.00
35
(2)

One of the first identified XPO1 inhibitors, although it is not used due to its toxic profile.

KPT185

1333151-73-7sc-487916
10 mg
$220.00
(0)

A selective inhibitor of XPO1 under investigation for its potential in targeting cancer cells.